SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (365)9/16/2004 4:43:42 PM
From: Icebrg  Respond to of 590
 
>>that represents very material earnings potential.>>

Provided the figure is in the same ballpark as for what Medarex likes to refer as cash-and-carry deals, Abgenix revenue should be between 30 and 50 mUSD for a billion dollar drug. It is of course better than nothing, but not by much.

Erik



To: nigel bates who wrote (365)9/16/2004 7:34:57 PM
From: keokalani'nui  Respond to of 590
 
>>Providing they didn't get CAT's lawyers to draw up the license agreement, <<

First, most big shot executives today make their deals before talking to their lawyers and, second, they often don't take their lawyers' advice!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News